Conmed (CNMD) Common Equity (2010 - 2026)

Conmed's Common Equity history runs 17 years deep, the most recent figure standing at $1.0 billion for Q1 2026.

• Quarterly Common Equity rose 4.1% year-over-year to $1.0 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.0 billion (up 4.1% YoY) and the FY2025 annual result came in at $1.0 billion, up 7.31% from the prior year.
• Common Equity was $1.0 billion for Q1 2026 at Conmed, down from $1.0 billion in the prior quarter.
• Across five years, Common Equity topped out at $1.0 billion in Q4 2025 and bottomed at $673.0 million in Q2 2022.
• A 5-year average of $868.2 million and a median of $854.7 million in 2024 frame the typical range for Common Equity.
• Annual changes were most pronounced in 2022 — Common Equity declined 9.61% — and 2024, when it increased 17.17%.
• Conmed's Common Equity stood at $745.5 million in 2022, then rose by 11.89% to $834.2 million in 2023, then climbed by 15.4% to $962.7 million in 2024, then grew by 7.31% to $1.0 billion in 2025, then slipped by 1.49% to $1.0 billion in 2026.
• Business Quant data shows CNMD's Common Equity at $1.0 billion in Q1 2026, $1.0 billion in Q4 2025, and $1.0 billion in Q3 2025.